type 1 diabetes Archives -

Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial –

Provention prices type 1 diabetes drug Tzield at $194,000

https://pharmaphorum.com/news/provention-prices-type-1-diabetes-drug-tzield-at-194000/

Market Access/ News/ News

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

Phil Taylor Diabetes, fda, Provention Bio, regulatory approval, Sanofi, teplizumab, type 1 diabetes, Tzield 0 Comment

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

https://pharmaphorum.com/news/provention-finally-gets-fda-nod-for-type-1-diabetes-drug-teplizumab/

News/ News/ R&D

Vertex buys diabetes cell therapy rival ViaCyte for $320m

Phil Taylor cell therapy, M&A, type 1 diabetes, Vertex Pharma, ViaCyte 0 Comment

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million

Vertex buys diabetes cell therapy rival ViaCyte for $320m

https://pharmaphorum.com/news/vertex-buys-diabetes-cell-therapy-rival-viacyte-for-320m/

R&D/ Views & Analysis/ Views and analysis

StartUp Health takes a multidisciplinary approach to fight type 1 diabetes

Jessica Hagen Cecelia Health, Diabetes, Startup Health, type 1 diabetes 0 Comment

David Weingard, chief impact officer of T1D Moonshot and founder of Cecelia Health, tells us how T1D Moonshot

StartUp Health takes a multidisciplinary approach to fight type 1 diabetes

https://pharmaphorum.com/r-d/startup-health-takes-a-multidisciplinary-approach-to-fight-type-1-diabetes/

Market Access/ News/ News

FDA sets August decision date for Provention’s type 1 diabetes drug

Phil Taylor antibody, fda, metabolic disease, Provention Bio, teplizumab, type 1 diabetes 0 Comment

Shares in Provention Bio cratered last July when the FDA turned down its marketing application for type 1

FDA sets August decision date for Provention’s type 1 diabetes drug

https://pharmaphorum.com/news/fda-sets-august-decision-date-for-proventions-type-1-diabetes-drug/

News/ News/ R&D

Vertex builds in gene editing yet again, with $1.2bn Arbor deal

Phil Taylor Arbor Biotechnologies, beta thalassaemia, CRISPR/Cas9, gene editing, sickle cell disease, type 1 diabetes, Vertex Pharma 0 Comment

Vertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of

Vertex builds in gene editing yet again, with $1.2bn Arbor deal

https://pharmaphorum.com/news/vertex-builds-in-gene-editing-yet-again-with-1-2bn-arbor-deal/

Market Access/ News/ News

FDA rejects Provention’s type 1 diabetes drug teplizumab

Phil Taylor Diabetes, fda, metabolic disease, Provention Bio, teplizumab, type 1 diabetes 0 Comment

The FDA indicated something was not well with Provention Bio’s filing for type 1 diabetes therapy teplizumab in

FDA rejects Provention’s type 1 diabetes drug teplizumab

https://pharmaphorum.com/news/fda-rejects-proventions-type-1-diabetes-drug-teplizumab/

Market Access/ News/ News

Artificial pancreas will be piloted in 1,000 diabetics, says NHS CEO

Phil Taylor artificial pancreas, continuous glucose monitoring, insulin, NHS England, NICE, Simon Stevens, type 1 diabetes 0 Comment

NHS England will provide artificial pancreas devices to 1,000 type 1 diabetes patients as part of a pilot

Artificial pancreas will be piloted in 1,000 diabetics, says NHS CEO

https://pharmaphorum.com/news/artificial-pancreas-will-be-piloted-in-1000-diabetics-says-nhs-ceo/

Market Access/ News/ News

Provention faces delay in FDA review of diabetes prevention antibody

Phil Taylor antibody, fda, metabolic disease, Provention Bio, teplizumab, type 1 diabetes 0 Comment

The FDA says it has uncovered “deficiencies” in the marketing application for Provention Bio’s much-anticipated drug teplizumab for

Provention faces delay in FDA review of diabetes prevention antibody

https://pharmaphorum.com/news/provention-faces-delay-in-fda-review-of-diabetes-prevention-antibody/

Trending

type 1 diabetes

Login